Gabriella Schivardi
A5000699221- Endometrial and Cervical Cancer Treatments
- Ovarian cancer diagnosis and treatment
- Cervical Cancer and HPV Research
- Endometriosis Research and Treatment
- Circular RNAs in diseases
- Uterine Myomas and Treatments
- Estrogen and related hormone effects
- Genetic factors in colorectal cancer
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
- Colorectal and Anal Carcinomas
- Epigenetics and DNA Methylation
- Multiple and Secondary Primary Cancers
- MicroRNA in disease regulation
- Intraperitoneal and Appendiceal Malignancies
- Renal cell carcinoma treatment
- Angiogenesis and VEGF in Cancer
- Reproductive System and Pregnancy
- Prostate Cancer Treatment and Research
- Surgical Simulation and Training
- Glioma Diagnosis and Treatment
- Vascular Malformations and Hemangiomas
- Gestational Diabetes Research and Management
- Biochemical Analysis and Sensing Techniques
- 14-3-3 protein interactions
European Institute of Oncology
2021-2025
Istituti di Ricovero e Cura a Carattere Scientifico
2022-2025
Mayo Clinic
2022-2025
Mayo Clinic in Arizona
2022-2023
WinnMed
2022-2023
Ripamonti
2023
University of Palermo
2022
Ospedale San Paolo
2022
University of Milan
2022
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
2018
No biomarkers are available to predict treatment response in patients with endometrial cancers who undergo fertility-sparing treatment. Therefore, we aimed evaluate the prognostic role of molecular classification. Patients cancer underwent progestins between 2005 and 2021 were retrospectively identified. Polymerase epsilon (POLE), TP53/p53, mismatch repair (MMR) proteins assessed assign groups: POLE mutated (POLEmut), MMR deficient (MMRd), no specific profile (NSMP), p53 abnormal (p53abn)....
<h3>Objective</h3> Ultrastaging is accurate in detecting nodal metastases, but increases costs and may not be necessary certain low-risk subgroups. In this study we examined the risk of involvement detected by sentinel lymph node (SLN) biopsy a large population apparent early-stage endometrial cancer stratified histopathologic characteristics. Furthermore, aimed to identify subgroup which ultrastaging omitted. <h3>Methods</h3> We retrospectively included patients who underwent SLN (with...
Objective To compare the risk class attribution with molecular classification unknown to those known, according European Society of Gynaecological Oncology/European for Radiotherapy and Pathology (ESGO/ESTRO/ESP) 2020 guidelines on endometrial cancer, a focus group migration. Additionally, evaluate capability novel analysis algorithm reduce number required tests. Methods We conducted retrospective study including all consecutive patients cancer undergoing surgery comprehensive analyses...
The prognostic significance of isolated tumor cells (≤0.2 mm) in sentinel lymph nodes (SLNs) endometrial cancer patients is still unclear. Our aim was to assess the value with low risk who underwent SLN biopsy and did not receive adjuvant therapy. Outcomes were compared node negative patients. Patients SLNs-isolated between 2013 2019 identified from 15 centers worldwide, while Mayo Clinic, Rochester, 2018. Only (stage IA, endometrioid histology, grade 1 or 2) any therapy included. Primary...
To assess the distribution of molecular classes and their impact on risk recurrence in endometrial cancer patients with lymph node metastasis at time primary surgery. Endometrial micrometastasis or macrometastasis (International Federation Gynecology Obstetrics (FIGO) 2009 stage IIIC) after surgical staging five referral centers worldwide from October 2013 to September 2022 who underwent classification were identified. cancers categorized into four classes: POLE mutated, mismatch repair...
OBJECTIVE: To compare the performance of four commonly used algorithms to differentiate benign from malignant adnexal masses when by a novice operator. METHODS: Women with treated at Mayo Clinic, Rochester, Minnesota, in 2019 were identified retrospectively. Patients included if they underwent surgery within 3 months diagnosis or had least 10 follow-up. A nonexpert operator (European Federation Societies for Ultrasound Medicine and Biology level I) classified each lesion using ADNEX...